An updated review on the diagnosis and assessment of post-treatment relapse in brain metastases using PET

References

• Le Rhun E, Guckenberger M, Smits M, et al., EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332–1347.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692–1704.
   PubMed Web of Science ®Google Scholar
• Langen KJ, Galldiks N, Hattingen E, et al. Advances in neuro-oncology imaging. Nat Rev Neurol. 2017;13(5):279–289.
   PubMed Web of Science ®Google Scholar
• Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–1060.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Kocher M, Ceccon G, et al. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro Oncol. 2020;22(1):17–30.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Langen KJ, Albert NL, et al. PET imaging in patients with brain metastasis-report of the RANO/PET group. Neuro Oncol. 2019;21(5):585–595.
   PubMed Web of Science ®Google Scholar
• Martin AM, Cagney DN, Catalano PJ, et al. Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol. 2018;4(8):1123–1124.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Kocher M, Langen KJ. Pseudoprogression after glioma therapy: an update. Expert Rev Neurother. 2017;17(11):1109–1115.
   PubMed Web of Science ®Google Scholar
• Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011 May;15(6):48.
   Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–542.
   PubMedGoogle Scholar
• Preusser M, Lim M, Hafler DA, et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11(9):504–514.
   PubMed Web of Science ®Google Scholar
• Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. Neuro Oncol. 2017;19(3):454–456.
   PubMed Web of Science ®Google Scholar
• Albert NL, Weller M, Suchorska B, et al. Response assessment in neuro-oncology working group and European Association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199–1208.
   PubMed Web of Science ®Google Scholar
• Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4(11):1334–1336.
   PubMed Web of Science ®Google Scholar
• Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96(3):191–197.
   PubMed Web of Science ®Google Scholar
• Belohlavek O, Simonova G, Kantorova I, et al. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Eur J Nucl Med Mol Imag. 2003;30(1):96–100.
   PubMed Web of Science ®Google Scholar
• Chernov M, Hayashi M, Izawa M, et al. Differentiation of the radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases: importance of multi-voxel proton MRS. Minim Invasive Neurosurg. 2005;48(4):228–234.
   PubMedGoogle Scholar
• Horky LL, Hsiao EM, Weiss SE, et al. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol. 2011;103(1):137–146.
   PubMed Web of Science ®Google Scholar
• Lai G, Mahadevan A, Hackney D, et al. Diagnostic accuracy of PET, SPECT, and arterial spin-labeling in differentiating tumor recurrence from necrosis in cerebral metastasis after stereotactic radiosurgery. AJNR Am J Neuroradiol. 2015;36(12):2250–2255.
   PubMed Web of Science ®Google Scholar
• Hatzoglou V, Yang TJ, Omuro A, et al. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro Oncol. 2016;18(6):873–880.
   PubMed Web of Science ®Google Scholar
• Tomura N, Kokubun M, Saginoya T, et al. Differentiation between treatment-induced necrosis and recurrent tumors in patients with metastatic brain tumors: comparison among (11)C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC-Preliminary Results. AJNR Am J Neuroradiol. 2017;38(8):1520–1527.
   PubMed Web of Science ®Google Scholar
• Otman H, Farce J, Meneret P, et al. Delayed [18 F]-FDG PET imaging increases diagnostic performance and reproducibility to differentiate recurrence of brain metastases from radionecrosis. Clin Nucl Med. 2022;47(9):800–806.
   PubMed Web of Science ®Google Scholar
• Grkovski M, Kohutek ZA, Schoder H, et al. (18)F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. Eur J Nucl Med Mol Imaging. 2020;47(6):1446–1457.
   PubMed Web of Science ®Google Scholar
• Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49(5):694–699.
   PubMed Web of Science ®Google Scholar
• Tsuyuguchi N, Sunada I, Iwai Y, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg. 2003;98(5):1056–1064.
   PubMed Web of Science ®Google Scholar
• Minamimoto R, Saginoya T, Kondo C, et al. Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-Methionine PET: visual Assessment versus Quantitative Assessment. PloS One. 2015;10(7):e0132515.
   PubMed Web of Science ®Google Scholar
• Govaerts CW, van Dijken BR, Stormezand GN, et al. (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases. Br J Radiol. 2021;94(1125):20210275.
   PubMed Web of Science ®Google Scholar
• Yomo S, Oguchi K. Prospective study of (11)C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment. BMC Cancer. 2017;17(1):713.
   PubMedGoogle Scholar
• Lizarraga KJ, Allen-Auerbach M, Czernin J, et al. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014;55(1):30–36.
   PubMed Web of Science ®Google Scholar
• Cicone F, Minniti G, Romano A, et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. Eur J Nucl Med Mol Imaging. 2015;42(1):103–111.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Stoffels G, Filss CP, et al. Role of O -(2-18 F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. J Nucl Med. 2012;53(9):1367–1374.
   PubMed Web of Science ®Google Scholar
• Ceccon G, Lohmann P, Stoffels G, et al. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol. 2017;19(2):281–288.
   PubMed Web of Science ®Google Scholar
• Romagna A, Unterrainer M, Schmid-Tannwald C, et al. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET-PET overcome diagnostic uncertainties? Radiat Oncol. 2016;11(1):139.
   PubMedGoogle Scholar
• Lohmann P, Stoffels G, Ceccon G, et al. Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase (18)F-FET PET accuracy without dynamic scans. Eur Radiol. 2017;27(7):2916–2927.
   PubMed Web of Science ®Google Scholar
• Heinzel A, Müller D, Yekta-Michael SS, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro Oncol. 2017;19(9):1271–1278.
   PubMed Web of Science ®Google Scholar
• Cicone F, Carideo L, Scaringi C, et al., Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET. Neuro Oncol. 2021;23(6):1024–1034.
   PubMed Web of Science ®Google Scholar
• Kebir S, Rauschenbach L, Galldiks N, et al., Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Neuro Oncol. 2016;18(10):1462–1464.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Abdulla DSY, Scheffler M, et al., Treatment Monitoring of Immunotherapy and Targeted Therapy Using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: initial Experiences. J Nucl Med. 2021;62(4):464–470.
   PubMed Web of Science ®Google Scholar
• Nguyen NC, Yee MK, Tuchayi AM, et al. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: a Pilot Study. Front Oncol. 2018;8(18). 10.3389/fonc.2018.00018
   Google Scholar
• Kasten BB, Udayakumar N, Leavenworth JW, et al. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics. 2019;9(17):5085–5104.
   PubMed Web of Science ®Google Scholar
• Wei W, Jiang D, Ehlerding EB, et al. Noninvasive PET Imaging of T cells. Trends Cancer. 2018;4(5):359–373.
   PubMed Web of Science ®Google Scholar
• England CG, Ehlerding EB, Hernandez R, et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017;58(1):162–168.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Lesniak WG, Nimmagadda S. Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. Mol Imaging. 2017;16:1536012117718459.
   Web of Science ®Google Scholar
• Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9(1):4664.
   PubMed Web of Science ®Google Scholar
• Niemeijer AN, Oprea Lager DE, Huisman MC, et al. First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer. J Nucl Med. 2021 Jun;63(6):899–905.
   Google Scholar
• Nienhuis PH, Antunes IF, Glaudemans A, et al. (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study. J Nucl Med. 2021;63(6):899–905.
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–577.
   PubMed Web of Science ®Google Scholar
• Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762.
   PubMed Web of Science ®Google Scholar
• Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–446.
   PubMed Web of Science ®Google Scholar
• Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30(9):1234–1248.
   PubMed Web of Science ®Google Scholar
• Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61(13):R150–166.
   PubMed Web of Science ®Google Scholar
• Zhou M, Scott J, Chaudhury B, et al. Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches. AJNR Am J Neuroradiol. 2018;39(2):208–216.
   PubMed Web of Science ®Google Scholar
• Charron O, Lallement A, Jarnet D, et al. Automatic detection and segmentation of brain metastases on multimodal MR images with a deep convolutional neural network. Comput Biol Med. 2018;95:43–54.
   PubMed Web of Science ®Google Scholar
• Grovik E, Yi D, Iv M, et al. Deep learning enables automatic detection and segmentation of brain metastases on multisequence MRI. J Magn Reson Imaging. 2019 Jan;51(1):175–182.
   Web of Science ®Google Scholar
• Rizzo S, Botta F, Raimondi S, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp. 2018;2(1):36.
   PubMedGoogle Scholar
• Gutsche R, Scheins J, Kocher M, et al. Evaluation of FET PET radiomics feature repeatability in glioma patients. Cancers (Basel). 2021;13(4):647.
   PubMed Web of Science ®Google Scholar
• Hotta M, Minamimoto R, Miwa K. 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier. Sci Rep. 2019;9(1):15666.
   PubMedGoogle Scholar
• Lohmann P, Kocher M, Ceccon G, et al. Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. Neuroimage Clin. 2018;20:537–542.
   PubMed Web of Science ®Google Scholar
• Soffietti R, Bettegowda C, Mellinghoff IK, et al. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncol. 2022;24(6):855–871.
   PubMed Web of Science ®Google Scholar
• Diaz M, Singh P, Kotchetkov IS, et al. Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases. J Neurooncol. 2022;157(1):81–90.
   PubMed Web of Science ®Google Scholar